Table 4.
Treatment Variables for Cocaine-Alcohol Dependent Males and Females Assigned to Naltrexone or Placebo Conditions during the 12-Week Trial
| Total Sample | Overall | Males | Females | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male Total | (A) | Female Total | PLAC | (B) | NTX | PLAC | (C) | NTX | ||
| Treatment Adherence | ||||||||||
| # CBT completers, n (%) | 54 (66.7) | 40 (67.8) | 14 (63.6) | 16 (61.5) | 24 (72.7) | 8 (72.7) | 6 (54.6) | |||
| # CBT sessions attended, M (sd) | 6.2 (3.9) | 6.6 (3.8) | 5.4 (4.0) | 6.1 (4.0) | 7.0 (3.6) | 4.1 (3.7) | 6.4 (4.1) | |||
| BRENDA completers, n (%) | 51 (61.5) | 35 (61.4) | 16 (61.5) | 17 (53.1) | 18 (72.0) | 9 (69.2) | 7 (53.9) | |||
| BRENDA sessions attended, M (sd) | 7.0 (3.8) | 7.5 (4.0) | 5.9 (3.1) | 7.0 (3.9) | 8.0 (4.0) | 7.6 (3.4) | * | 4.7 (2.4) | ||
| Percentage of days taking medication,M% (sd) | 61.0 (36.0) | 62.4 (36.0) | 57.6 (36.3) | 58.0 (35.0) | 66.9 (36.7) | 60.9 (36.3) | 54.4 (36.9) | |||
| Med. Compliance > 80%, n (%) | 75 (45.7) | 54 (46.6) | 21 (43.8) | 24 (41.4) | 30 (51.7) | 11 (45.8) | 10 (41.7) | |||
| Cocaine/Alcohol Use in Treatment | ||||||||||
| Cocaine use days, M (sd) | 7.4 (11.6) | 7.2 (11.1) | 7.7 (13.0) | 9.0 (12.7) | 5.3 (8.8) | 6.2 (10.1) | 9.4 (15.6) | |||
| Money spent on cocaine, M$ (sd) | 465 (1045) | 432 (795) | 543 (1,488) | 478 (761) | 384 (833) | 495 (1,505) | 593 (1,502) | |||
| Alcohol use days, M (sd) | 9.7 (12.9) | 9.7 (13.1) | 9.7 (12.6) | 11.3 (13.6) | 8.1 (12.5) | 8.8 (11.0) | 10.6 (14.2) | |||
| Percentage of days drinking, M% (sd) | 11.9 (15.0) | 11.8 (15.2) | 12.3 (14.5) | 14.4 (16.2) | 9.1 (13.7) | 9.8 (12.0) | 14.8 (16.6) | |||
| Percentage of days heavy drinking, M% (sd) | 7.6 (11.4) | 7.6 (11.4) | 7.4 (11.3) | 9.6 (12.7) | 5.6 (9.6) | 7.8 (12.2) | 6.9 (10.6) | |||
| Number of drinks per drinking, M (sd) | 5.2 (5.2) | 5.2 (5.2) | 5.0 (5.4) | 5.6 (6.0) | 4.9 (4.2) | 6.4 (6.7) | 3.7 (3.1) | |||
| Percentage of clean UDS - cocaine (1) M % (sd) | 40.0 (32.2) | 43.3 (32.2) | * | 32.3 (31.3) | 37.1 (31.6) | * | 49.4 (31.8) | 39.2 (36.0) | 25.4 (24.6) | |
*
p < 0.05
(1)
Missing UDS assumed drug positive (Reviewer #1)
(A)
Test of Male vs. Female
(B)
Test of Naltrexone vs. Placebo in Males only
(C)
Test of Naltrexone vs. Placebo in Females only
Note: M= Mean; M%= Mean percentage; sd=standard deviation; CBT=cognitive behavior therapy; PLAC= placebo; NTX=high dose naltrexone